Results 61 to 70 of about 45,441 (213)
The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma [PDF]
, 2008 We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase inhibitor (HDACi), PCI-24781. PCI-24781 was studied alone and combined with bortezomib in Hodgkin lymphoma (L428) and non-Hodgkin's ...
Andrew Evens +9 more
core +1 more source
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, EarlyView.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Rare Tumors, 2015 We present a case of a pleural space malignancy masked by an atypical presentation of mantle cell lymphoma. Our patient presented with a large pleural effusion and right sided pleural studding, initially attributed to a new diagnosis of mantle cell ...
Luke Masha +2 more
doaj +1 more source
Recurrent mantle cell lymphoma in the uterine cervix: a case report
Journal of Medical Case Reports, 2020 Background Mantle cell lymphoma is one of several subtypes of non-Hodgkin lymphoma. Cervical relapse of non-Hodgkin lymphoma is a very rare condition that has a variable and nonspecific presentation and may resemble other neoplastic or inflammatory ...
Giusi Santangelo +10 more
doaj +1 more source
Eccrine poromatosis following chemotherapy and radiation therapy [PDF]
, 2019 Eccrine poroma presents as a single, symptomless erythematous papule in areas with a high density of eccrine sweat glands. Although rare, eccrine poromas can present as multiple lesions, otherwise known as eccrine poromatosis.
Chiu, Melvin, Kim, Gene, Nguyen, Khoa
core
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley +1 more source
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Journal of Hematology & Oncology, 2018 Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji +5 more
doaj +1 more source
Evaluation of FilmArray Multiplex PCR Test Results in Bloodstream Infections in Oncological Patients
Journal of Clinical Laboratory Analysis, EarlyView.In this study conducted at an oncology hospital, BCID2 panel results for the rapid identification of microorganisms and resistance genes in positive blood culture samples were compared with conventional culture methods. The BCID2 panel provided faster results and showed a high correlation with traditional methods.
İpek Mumcuoğlu +6 more
wiley +1 more source
Hematology, Transfusion and Cell Therapy, 2018 Objective: Follicular and mantle cell lymphoma are low-grade B-cell malignancies that lack good responses to chemoimmunotherapy. This study aimed to assess retrospectively clinicopathological features and to determine independent prognostic factors for ...
Guilherme Rossi Assis-Mendonça +8 more
doaj +1 more source
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study [PDF]
, 2017 Background: Relapsed or refractory diffuse large B-cell and mantle-cell lymphoma have a poor prognosis. The EPOCH regimen and rituximab monotherapy have demonstrated activity as salvage therapies.
Betticher, D. C. +8 more
core